Interv Akut Kardiol. 2018;17(3):185-187

The EXSCEL trial: effect of exenatide on cardiovascular safety

Jiří Vítovec, Lenka ©pinarová
I. interní kardioangiologická klinika FN u sv. Anny a LF MU, Brno

The EXSCEL clinical trail compared exenatide, a GLP-1 receptor agonist, and placebo among patients with type-2 diabetes withor without previous cardiovascular disease. The trial tested the safety hypothesis (non inferiority) and efficacy hypothesis (superiority).Exenatide, administered once weekly, was noninferior to placebo with respect to safety (P < 0.001 for noninferiority) butwas not superior to placebo with respect to efficacy (P = 0.06 for superiority).

Keywords: cardiovascular safety, type 2 diabetes mellitus – exenatide, EXSCEL trial

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinarová L. The EXSCEL trial: effect of exenatide on cardiovascular safety. Interv Akut Kardiol. 2018;17(3):185-187.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Niessner A, Tamargo J, Koller L, et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the ESC Working Group on Cardiovascular Pharmacotherapy. Europ Heart J 2018; 39: 2274-2281. Go to original source... Go to PubMed...
    2. Peruąičová J. Exenatide. Remedia 2008; 18: 18-23. Go to original source...
    3. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239. Go to original source... Go to PubMed...
    4. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2017; published online Dec 6. http://dx.doi. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.